On the recordMarch 5, 2012
These capital-intensive firms face unique challenges in raising the significant amounts of money necessary to complete clinical trials and complete development of cutting-edge drugs.
Source
congress.govBob Corker: “These capital-intensive firms face unique challenges in raising the significant amounts of money necessary to complete…”
Editor's note · Context
Corker highlights challenges faced by biotech firms in raising capital.
Share
More from Bob Corker
Dec 6, 2018
I wish to speak on S. 1862, the Trafficking Victims Protection Reauthorization Act of 2017.
Dec 12, 2018
I ask again the Senator: For those of us, many in this body, including the Senator from Indiana, who worry that the mere refueling that may take place in Mali, where maybe we are supporting French troops, or the refueling in other…
Dec 4, 2018
What I do know is that... the CIA director came in and with some analysts and gave the most precise presentation I've ever heard in 12 years.
Oct 16, 2019
The question is, why would you say you're going to pull our troops out and lose control of a third of the country and do the things that caused us to lose all of our leverage and then go to Turkey with hat in hand and ask them to do…
Other voices in this conversation
